Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalstrokeequal tosubjectsalzheimer
  Phrases that lowered it: and safetyefficacy andsafety ofthe efficacyplaque
• Sponsor's past termination rate: 16.5% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 342 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past trials: 556 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Drug's FAERS reports with a death: 12.7% (lowers risk) · Drug's FDA history
• Maximum age: not given (lowers risk) · Who can join
• Blinding: triple (raises risk) · Design
• Minimum age: 50 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 71.9% (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 4866 (raises risk) · Drug's FDA history
• Disease area, psychiatry: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients NCT01485302 · started 2012 · scored riskier than 60% of active trials completed
• Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease NCT00602680 · started 2008 · scored riskier than 27% of active trials terminated
• Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil NCT01266525 · started 2011 · scored riskier than 62% of active trials completed
• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease NCT04994483 · started 2021 · scored riskier than 83% of active trials completed
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease NCT05026177 · started 2021 · scored riskier than 91% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.